GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » Future 3-5Y Total Revenue Growth Rate

LadRx (LADX) Future 3-5Y Total Revenue Growth Rate : N/A (As of May. 11, 2025)


View and export this data going back to 1986. Start your Free Trial

What is LadRx Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, LadRx's Future 3-5Y Total Revenue Growth Rate is N/A.


Competitive Comparison of LadRx's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, LadRx's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LadRx's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LadRx's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where LadRx's Future 3-5Y Total Revenue Growth Rate falls into.


;
;

LadRx  (OTCPK:LADX) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


LadRx Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of LadRx's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


LadRx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » Future 3-5Y Total Revenue Growth Rate
Traded in Other Exchanges
N/A
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Executives
Cary J Claiborne director 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Stephen Snowdy officer: Chief Executive Officer C/O CYTRX CORPORATION, 11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES CA 90049
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Eric Curtis officer: Pres., Chief Operating Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Felix Kratz officer: Vice President Drug Discovery 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joel K Caldwell director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Chawla Shanta M.d. officer: Senior VP-Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Earl W Brien director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Olivia C Ware officer: Chief Commercial Officer 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Eric Jay Selter director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Anita J Chawla director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joseph Rubinfeld director C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568
Douglas Scott Wieland officer: Sr VP - Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Louis Ignarro director 11726 SAN VICENTE BLVD, STE 650, LOS ANGELES CA 90049

LadRx Headlines

From GuruFocus

CytRx Corporation Reports First Quarter 2019 Financial Results

By PRNewswire PRNewswire 05-15-2019